Skip to content

Safety database in OnePV

Every ICSR, from book-in to E2B(R3)

The pharmacovigilance safety database at the centre of OnePV: ICSR processing, MedDRA and WHODrug coding, narratives, quality and medical review, with a full audit trail.

  • 10+years in the industry
  • 300+clients
  • 55+inspections behind us

A sample case record, US-EXAMPLE-0522, drawn as seven stacked sections of the ICH E2B(R3) message. C.1, identification of the case safety report: Day 0 is 3 November 2026. C.2.r, primary source: a physician in the United States. C.3, sender: Northbridge Pharma. D, patient: female, 54 years. E.i, reaction: anaphylactic reaction, MedDRA lowest level term and preferred term 10002198. G.k, drug: Exampril 10 mg tablets, suspect. H, narrative: drafted by Gen AI, reviewed and signed by the safety physician.

Sample data. Exampril and Northbridge Pharma are fictional.

Trusted by 300+ clients, including

  • Novartis
  • Cipla
  • Fortrea
  • Cosette Pharmaceuticals
  • Polpharma
  • Wipro
  • Himalaya
  • ProPharma Group
  • Zydus
  • Harrow
  • Freyr
  • SynapMed
  • Somerset Therapeutics
  • Veloxis Pharmaceuticals
  • APCER Life Sciences
  • Navatio
  • Persistent
  • Bio-Ethica
  • RQM+
  • 4C Pharma Solutions
  • Norwich Pharma Services
  • SentinelRX
  • Pharmazz
  • Alpha-Cure

Anatomy of a case record

Each case is one record, in the sections ICH E2B(R3) defines. Book-in, coding, review, signature and submission all land on that one record.

  • C.1 Identification of the case safety report

    E2B(R3) is built from this same record and submitted to FDA, EMA, MHRA and Health Canada.

  • C.1.4 Date first received

    Day 0: the first receipt of the four minimum criteria; the reporting clock runs from here.

    3 Nov 2026 · Day 0

  • C.2.r Primary source(s) of information

    Physician, United States

  • C.3 Information on sender

    Northbridge Pharma

  • D Patient characteristics

    Female, 54 years

  • E.i Reaction(s) / event(s)

    Coded in MedDRA.

    Reported as “anaphylactic reaction” LLT and PT 10002198 SOC Immune system disorders Seriousness (E.i.3.2): caused or prolonged hospitalisation

  • G.k Drug(s) information

    Coded in WHODrug.

    Exampril 10 mg tablets G.k.1 characterisation of drug role: suspect

  • G.k.9.i.2.r Relatedness of drug to reaction(s) / event(s)

    The reporter’s and the company’s assessments are kept separately; the company’s is recorded at medical review.

    Reporter: related Company: assessed at medical review

  • H.1 Case narrative

    Gen AI drafts it; a safety physician reviews it and signs.

  • Across the record

    Every field change versioned and attributable, with e-signature where required.

Sample data from case US-EXAMPLE-0522; Exampril and Northbridge Pharma are fictional. Serious and unexpected, so the 15-day report is due 18 Nov 2026. Expectedness is the company’s assessment against the reference safety information; ICH E2B(R3) has no data element for it, so it carries no ID here.

From information to submission

The work on a case

Each step lands on the same case record, in configurable workflows. Your case processors and safety physicians check what Gen AI extracts and approve what it drafts.

  1. Book-in

    Day 0: the first receipt of the four minimum criteria.

    3 Nov 2026 Day 0

  2. Triage

    Seriousness and expectedness set the reporting clock.

    Serious, unexpected Due 18 Nov 2026

  3. Data entry

    Gen AI extracts the fields from the source; the case processor checks each one.

  4. Coding

    MedDRA for the reaction, WHODrug for the drug.

    LLT/PT 10002198 Exampril 10 mg tablets

  5. Quality review

    A reviewer checks the case for completeness and accuracy before medical review.

  6. Medical review

    A safety physician assesses causality and records the company assessment.

    Reporter: related Company: recorded here

  7. Approval

    E-signature, with the signer, the date and time, and its meaning.

  8. Submission

    E2B(R3) built from the record.

    To FDA Sent on day 2 of 15

Sample data from case US-EXAMPLE-0522. Exampril is fictional.

At the centre of OnePV

Case intake and literature management feed the safety database. E2B(R3) submissions are built from it, and signal detection and PV agreements work from the same data.

Case intake

Email, web forms, call centre (MICC) and partner reports in one triage queue.

Literature management

PubMed and Embase; relevant articles become cases inside the safety workflow.

Safety database

ICSR processing, coding and medical review

E2B(R3) submission

  • FDA
  • EMA
  • MHRA
  • Health Canada

Signal detection

PRR, ROR and EBGM, with a recorded decision for every signal.

PV agreements (SDEA)

Safety data exchange agreements, working from the same data.

One system for patients, medical devices, cosmetics and veterinary medicines. Veterinary Safety runs on the same safety database.

Compliance and validation

IQ/OQ/PQ validation is part of every engagement, not a paid add-on.

IQInstallation
qualification
OQOperational
qualification
PQPerformance
qualification

Standards and how the safety database meets each
StandardHow the safety database meets it
21 CFR Part 11Built for. Every field change is versioned and attributable, with e-signature where required.
EU Annex 11Built for computerised systems in GxP use, with a full audit trail.
GxP and GAMP 5Built for. IQ/OQ/PQ validation included in every engagement.
ICH E2B(R3)Submission to FDA, EMA, MHRA and Health Canada, built from the case record.
GDPR and HIPAABuilt for.
ISO 9001 and ISO 27001Clinevo is certified for quality management and information security.
SOC 2 Type IIClinevo is independently audited for security, with its controls tested over a period of operation.

Moving from your current safety database

Four steps from discovery to live submissions, with your historical cases moved across and your team trained by role.

  1. Discovery and scoping

    Your products, case volumes, reporting obligations, partners and current system.

  2. Configuration and validation

    Workflows, reporting rules and roles configured, then validated with IQ/OQ/PQ.

  3. Data migration and training

    Historical cases moved from your current safety database; role-based training for case processors, physicians and administrators.

  4. Go-live and support

    Live submissions, with 24/7 support.

What a Head of Drug Safety says

“With Clinevo Safety, we have transformed our adverse event reporting process. Submitting over 10,000 cases annually to the USFDA and EMA has never been smoother.”

Head of Drug Safety, US-based pharma
  • 10+years in the industry
  • 300+clients
  • 55+inspections behind us

Enterprise Software without enterprise costs

hello@clinevotech.com+91 98201 03201